Dose Study of Antithymocyteglobulin in Haploidentical Allogeneic Stem Cell Transplantation
Status:
Unknown status
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the incidences of GVHD in haploidentical
hematopoietic stem cell transplant recipients receiving different dose of antithymocyte
globulin (ATG) for acute graft-versus-host disease(aGVHD) prophylaxis. The investigators'
first objective was to investigate the optimal dose of ATG for aGVHD.
Phase:
N/A
Details
Lead Sponsor:
Nanfang Hospital of Southern Medical University
Collaborators:
Central South University Xiangya Hospital Fujian Medical University Peking University People's Hospital